TMS – Transcranial Magnetic Stimulation + Ketamine Therapy
Documented synergy between TMS – Transcranial Magnetic Stimulation and Ketamine Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Non-invasive brain neuromodulation for mind and performance
Definition and how it works: Transcranial Magnetic Stimulation (TMS) uses rapid magnetic pulses to induce electrical currents in specific regions of the cerebral cortex, modulating neuronal excitability. Repetitive TMS (rTMS) can increase or decrease the activity of specific brain regions depending on the frequency used. It is FDA-approved for treatment-resistant major depression, OCD and migraines, and is widely investigated for cognitive optimisation, ADHD, PTSD and addictions.
Transcranial Magnetic Stimulation (TMS) uses rapid magnetic pulses to induce electrical currents in specific regions of the cerebral cortex, modulating neuronal excitability. Repetitive TMS (rTMS) can increase or decrease the activity of specific brain regions depending on the frequency used. It is FDA-approved for treatment-resistant major depression, OCD and migraines, and is widely investigated for cognitive optimisation, ADHD, PTSD and addictions.
Origin and history
TMS was developed by Anthony Barker in Sheffield (UK) in 1985. The FDA approved it for depression in 2008 and for OCD in 2018. The TBS protocol was developed in the early 2000s and represents the most significant advance in treatment efficiency.
1. Neurological assessment Clinical history, depression/anxiety scales (PHQ-9, GAD-7). Optional EEG.
2. Mapping and targeting Localisation of the DLPFC (left dorsolateral prefrontal cortex) or target zone via neuronavigation.
3. TMS session 10–20 min. 10 Hz rTMS (activating) or 1 Hz (inhibiting). iTBS protocol: 3 min equivalent.
4. 4–6 week protocol 20–30 sessions, 5 days/week. No anaesthesia or sedation. Patient remains awake.
5. Follow-up and maintenance Response evaluation every 10 sessions. Weekly or monthly maintenance post-remission.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| TMS system with neuronavigation | MagVenture MagPro / Magstim Horizon | Figure-of-eight coil. MRI-guided neuronavigation for millimetre precision. |
| FDA-approved iTBS system | Neuronetics NeuroStar / BrainsWay Deep TMS | 3-minute protocol FDA-approved 2018. H-coil for deep stimulation. |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Non-invasive brain neuromodulation for mind and performance
€100–250 per session
20–30 sessions (5 days/week, 4–6 weeks) for depression; optimisation protocols: 10–20 sessions
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between TMS – Transcranial Magnetic Stimulation and Ketamine Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between TMS – Transcranial Magnetic Stimulation and NAD+ IV Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between TMS – Transcranial Magnetic Stimulation and Biomarker Testing. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
More than 2,500 clinical studies support TMS. The response rate in treatment-resistant major depression is 50–60% and remission 30–35% according to meta-analyses in the NEJM. The iTBS (intermittent Theta Burst Stimulation) protocol approved in 2018 achieves results equivalent to conventional TMS in 3 minutes. Neuroimaging studies confirm changes in Default Mode Network and frontolimbic connectivity.
2026 SR/MA (12 studies, n=1,318): TMS significantly reduces depressive symptomatology (HAMD -4.47 points; p<0.00001) and MADRS in major depressive disorder patients.
2026 SR/MA (13 studies, n=625; 6 RCTs): accelerated TMS showed NO significant advantage over sham or standard TMS for suicidality reduction. Adverse effects more frequent (OR 1.95). Non-significant favourable trend for aTMS.
2026 SR/MA (27 RCTs, n=868): neuromodulation significantly reduces OCD symptoms vs control. Fronto-limbic deep brain stimulation showed largest Y-BOCS improvements. Invasive neuromodulation more effective than non-invasive approaches.
2026 network meta-analysis (77 studies, Alzheimer's and MCI): rTMS, tACS and tDCS significantly improve global cognitive function (MMSE, MoCA and ADAS-cog). tDCS superior to rTMS in MMSE/MoCA, but rTMS more effective in ADAS-cog.
Last bibliographic review: 2026-03-28.
The most common are mild scalp discomfort and temporary headache that resolve within 1–2 days. The risk of seizure is very low (<0.1%) with current protocols in appropriately selected patients.
Yes, TMS is compatible with most medications. Some studies suggest that the combination of TMS plus antidepressant is more effective than either alone.
In depression, studies show maintenance of remission in 60–70% of patients at one year. Maintenance protocols (one session weekly or monthly) significantly extend the duration of benefit.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with TMS – Transcranial Magnetic Stimulation.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology